CFDA Reviews Spate Of J&J Product Recalls, Seeks Quality Commitments
This article was originally published in PharmAsia News
Executive Summary
China FDA officials recently met with executives of Johnson & Johnson to review a spate of product recalls in China since 2009, with requesting the company to identify and rectify quality management system flaws by instituting risk control measures and adhering to Chinese laws and technical standards.
You may also be interested in...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.